JPRN-UMIN000008361已完成未知
Multicenter, randomized, double-blind, placebo controlled, parallel group trial to evaluate the effect of Vitamin D supplementation for fall prevention - Effect of Vitamin D supplementation for fall prevention
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •History of kidney stones or ureterolithiasis. Clinically significant hepatic, cardiac, or renal insufficiency Hypercalcemia Malabsorption syndrome Consumption of medications known to interfere with vitamin D metabolism History of hypersensitivity reactions to vitamin D Any other conditions deemed unsuitable for trial as evaluated by the physician-in-charge Subject who refuse to participate in this study
研究者
相似试验
进行中（未招募）
1 期
Adjustment and improvement of metabolic control in night shift workers after administration of melatoniEUCTR2012-005254-30-DEniversity Medical Center Hamburg-Eppendorf144
进行中（未招募）
1 期
Placebo controlled study to assess the efficacy and safety of rapamycin in drug resistant epilepsy associated with tuberous sclerosis complexEUCTR2021-004548-64-PLThe Children's Memorial Health Institute200
进行中（未招募）
不适用
Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformin BM18106type 2 diabetesMedDRA version: 6.1Level: PTClassification code 10049746EUCTR2004-004529-84-ITROCHE200
进行中（未招募）
不适用
Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformiEUCTR2004-004529-84-DEF. Hoffmann-La Roche Ltd200
已完成
不适用
Multicenter, randomized, double-blind, placebo-controlled, parallel groups of efficacy and safety of WelChol® in type 2 diabetic patients on insulin therapy alone or insulin in combination with other oral antidiabetics in inadequate glycemic control-E10 Insulin-dependent diabetes mellitusInsulin-dependent diabetes mellitusE10PER-038-05SANKYO PHARMA DEVELOPMENT,